Clinical Trial Update: BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating BMS-986205 in combination with nivolumab for hepatocellular carcinoma across first- or second-line settings; study terminated with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• BMS-986205 (BMS-986205)
• nivolumab (nivolumab)

Snippet

Sponsor: Edward Kim | Conditions: Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-08-22